Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries - Archive ouverte HAL Access content directly
Journal Articles International Journal of Cardiology Year : 2014

Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries

(1, 2, 3, 4, 5) , (1, 2, 3, 4, 5) , (6)
1
2
3
4
5
6

Abstract

Numerous registries, including the most recent ESC Euro-observational registry, have reported a large and persistent gap between real-life practice in the use of life-saving evidence-based therapies (such as renin angiotensin antagonists, beta-blockers, mineralocorticoid receptor antagonists) and recommended practices in international guidelines. Although the use of multiple renin angiotensin aldosterone system-inhibitors is associated with the development of worsening renal function and hyperkalemia in patients with heart failure and reduced ejection fraction, increased efforts should be expended to initiate and maintain target doses of these agents so as to provide their benefits on mortality and hospitalizations for heart failure.
Not file

Dates and versions

hal-01739948 , version 1 (21-03-2018)

Identifiers

Cite

Patrick Rossignol, Faiez Zannad, Bertram Pitt. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries. International Journal of Cardiology, 2014, 177 (3), pp.731 - 733. ⟨10.1016/j.ijcard.2014.11.004⟩. ⟨hal-01739948⟩
24 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More